Daily Stock Analysis, ACER, Opexa Therapeutics Inc, priceseries

Opexa Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
19.90
Close
19.91
High
20.33
Low
19.30
Previous Close
19.83
Daily Price Gain
0.08
YTD High
28.25
YTD High Date
Apr 11, 2019
YTD Low
19.30
YTD Low Date
Apr 24, 2019
YTD Price Change
-1.54
YTD Gain
-7.18%
52 Week High
34.10
52 Week High Date
Aug 22, 2018
52 Week Low
16.02
52 Week Low Date
Dec 17, 2018
52 Week Price Change
1.01
52 Week Gain
5.34%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 3. 2018
21.10
Aug 16. 2018
26.27
9 Trading Days
24.52%
Link
LONG
Aug 17. 2018
28.94
Sep 6. 2018
31.32
13 Trading Days
8.24%
Link
LONG
Dec 31. 2018
20.12
Jan 24. 2019
24.12
16 Trading Days
19.89%
Link
Company Information
Stock Symbol
ACER
Exchange
NasdaqCM
Company URL
http://www.opexatherapeutics.com
Company Phone
(281) 272-9331
CEO
Neil K. Warma
Headquarters
Texas
Business Address
2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS, TX 77381
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001069308
About

Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX.

Description

Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases based on its proprietary T-cell technology. The company's lead product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. It is also developing OPX-212 as an autologous T-cell immunotherapy that is in preclinical development to treat neuromyelitis optica. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics, Inc. was founded in 2003 and is based in The Woodlands, Texas.